We recently demonstrated that platelet aggregation occurred in fibrinogen-deficient mice. In these animals, platelet fibronectin (Fn) content was increased 3-5 fold, suggesting that Fn may also be involved in platelet aggregation. Methods and results: We compared platelet Fn content from a severe hypofibrinogenemic patient (with approximately 0.5% of normal fibrinogen levels) with his parents (heterozygous) and healthy donors. A significant increase in the patientÕs platelet Fn content was detected by immunoblot, flow cytometry, and immunoelectron microscopy (IEM). To examine the possible contribution of platelet Fn to platelet aggregation, we examined cell-surface Fn expression after thrombin treatment. Unexpectedly, IEM detected only trace amounts of Fn retained on the patientÕs platelet surface, and flow cytometry indicated that surface Fn was approximately 6-fold lower than that of his parents and tenfold lower than that of healthy donors. An ELISA further confirmed that the patientÕs platelet Fn was primarily released into the extracellular medium. To test whether retention of surface Fn was due to fibrin formation on the platelet surface, an antifibrin antibody (T2 G1) was employed. Fibrin was detected on platelets from healthy donors and from the father, but was negligible on the patientÕs platelets. Consistent with these data, when gel-filtered platelets of healthy donors were treated with thrombin receptor activation peptide (SFLLRN-NH 2 ; no conversion of fibrinogen to fibrin), little surface Fn was detected. Conclusion: Fibrinogen not only competitively inhibits human platelet Fn internalization but also controls platelet-surface Fn retention via fibrin formation. The Fn-fibrin interaction is one possible mechanism to promote Fn interaction with platelets.
Summary. Background:
We recently demonstrated that platelet aggregation occurred in fibrinogen-deficient mice. In these animals, platelet fibronectin (Fn) content was increased 3-5 fold, suggesting that Fn may also be involved in platelet aggregation. Methods and results: We compared platelet Fn content from a severe hypofibrinogenemic patient (with approximately 0.5% of normal fibrinogen levels) with his parents (heterozygous) and healthy donors. A significant increase in the patientÕs platelet Fn content was detected by immunoblot, flow cytometry, and immunoelectron microscopy (IEM). To examine the possible contribution of platelet Fn to platelet aggregation, we examined cell-surface Fn expression after thrombin treatment. Unexpectedly, IEM detected only trace amounts of Fn retained on the patientÕs platelet surface, and flow cytometry indicated that surface Fn was approximately 6-fold lower than that of his parents and tenfold lower than that of healthy donors. An ELISA further confirmed that the patientÕs platelet Fn was primarily released into the extracellular medium. To test whether retention of surface Fn was due to fibrin formation on the platelet surface, an antifibrin antibody (T2 G1) was employed. Fibrin was detected on platelets from healthy donors and from the father, but was negligible on the patientÕs platelets. Consistent with these data, when gel-filtered platelets of healthy donors were treated with
Introduction
Platelet adhesion and subsequent aggregation at the site of vascular injury is one of two important mechanisms required to stop bleeding; the other is the coagulation system, which generates thrombin, coverts fibrinogen to fibrin, and subsequently forms the polymerized fibrin matrix. Thrombin generated from the coagulation system is also the most potent platelet agonist, which induces platelet activation and granule release. Although activation of platelets and the coagulation system is essential for the arrest of bleeding, the same hemostatic processes also contribute to the generation of inopportune thrombi within atherosclerotic arteries, which is the leading cause of morbidity and mortality worldwide [1] .
It has been demonstrated that von Willebrand factor (VWF) and fibrinogen are two key molecules that mediate platelet adhesion and aggregation [2] . However, we recently demonstrated that thrombus formation and platelet aggregation still occurred in mice lacking both VWF and fibrinogen [3, 4] . In fibrinogen-deficient and/or fibrinogen and VWF doubledeficient mice, platelet fibronectin (Fn) was increased 3-5 fold [3] . This was due to enhanced internalization of plasma Fn by the platelet a IIb b 3 integrin (GPIIbIIIa) after depletion of fibrinogen (a competitive ligand for the same a IIb b 3 integrin) [5] . We subsequently demonstrated that plasma Fn promotes thrombus growth and stability in injured arterioles [6] . These results are consistent with recent observations that Fn selfassembly may be involved in thrombosis and hemostasis [7] [8] [9] .
However, it is unclear whether the supportive role of plasma Fn in thrombus formation was due to its contribution to platelet aggregation. There is also no report regarding fibrinogen control of human plasma Fn internalization.
In the present study, we examined platelet Fn content in a human patient with severe hypofibrinogenemia [10] and found that the patientÕs platelet Fn content was significantly increased. Unexpectedly, this excess Fn was not efficiently retained on the platelet surface after thrombin treatment. We demonstrated that fibrin converted from platelet-released fibrinogen is important for cell-surface Fn retention. The role of plateletreleased Fn in thrombosis and hemostasis is discussed.
Materials and methods

Human subjects
The patient with severe hypofibrinogenemia (homozygous) was a 30-year-old male who was born from parents (heterozygous) of a consanguineous marriage. The patient had a plasma fibrinogen level of 1.7 mg dL )1 (approximately 200 times lower than normal) and a platelet aggregation ratio of 10-20% (about 4-6 times lower than the normal level). His father and mother (53 years old) had fibrinogen levels that were approximately 50% of normal. Their clinical manifestation and genetic diagnosis had been reported previously [10] . Three healthy blood donors (two males and one female, aged 30, 40 and 45 years, respectively) were used as controls. Informed consent was obtained for each subject in accordance with the Declaration of Helsinki. This study was approved by the institutional review board.
Platelet preparation and aggregation
Blood samples from individual subjects were collected into a tube containing 3.8% sodium citrate (1/9 v/v). Platelet-rich plasma (PRP) was obtained by centrifugation at 300 · g for 7 min. Platelets were then isolated from the PRP by gel filtration on a Sepharose 2B column (Sigma, St Louis, MO, USA) in PIPES buffer (PIPES 5 mM, NaCl 1.37 mM, KCl 4 mM, glucose 0.1%, pH 7.0) as previously described [3, 4, 10, 11] . Platelet aggregation assays in the patientÕs PRP before and after fibrinogen transfusion (0.06 g kg ) were performed as we previously described [10] . Briefly, 250 lL PRP was prewarmed at 37°C for 10 min. Platelet aggregation was then induced with 10 lM adenosine diphosphate (ADP; Sigma, St Louis, MO, USA) and recorded on a computerized aggregometer (ChronoLog Corp., Havertown, PA, USA).
Platelet activation and permeabilization
Gel-filtered platelets were activated with 1.5U mL 
Immunogold labeling and immunoelectron microscope
The permeabilized and the activated gel-filtered platelets were incubated with individual antibodies against Fn, fibrinogen, or fibrin (as above), followed by incubation with goldconjugated goat antimouse IgG or gold-conjugated goat antirabbit IgG (Kehao Bioscience, Beijing, China) for 1 h. The immunogold-labeled platelets were centrifuged at 500 · g for 15 min. The platelet pellets were fixed with 5% glutaraldehyde, embedded onto paraffin, and sliced using a super-microtome (LKD, Bremma, Sweden). Platelet samples were then studied with a JEM 1230 perspective electron microscope (JEOL Ltd, Tokyo, Japan).
Western blot
Gel-filtered platelets were centrifuged at 2000 · g for 10 min at room temperature, and lyzed in lysis buffer [0.2% sodium dodecyl sulfate (SDS), 10% glycerol, 100 mM Tris-HCl, 4 mM ethylenediamine tetraacetic acid, 4 mM phenylmethylsulfonyl fluoride, 100 mM dithiothreitol, and 0.002% bromophenol blue]. The samples were boiled for 10 min and subjected to 6% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred to immobilon-P polyvinylidene fluoride (PVDF) membrane (Hybond-P, Amersham Pharmacia Biotech, Baie d'Urfe, Canada). After blocking with 20 mM Tris-Cl, pH 7.6, containing 137 mM NaCl, 0.1% Tween-20
Fibronectin in thrombosis and hemostasis 1741 and 5% non-fat milk, the membrane was incubated with a 1:2000 dilution of antifibrinogen, Fn, and TSP-1 antibodies (above) at room temperature for 2 h. A mouse antihuman vinculin antibody (Clone hVIN-1, Sigma) was used as an internal control for equal protein loading. The membrane was then incubated with alkaline-phosphatase-conjugated antimouse or antirabbit polyvalent immunoglobulins. Immunoreactive bands were visualized by reaction with substrate (5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium, Sigma).
To detect factor (F) XIII levels, platelet and plasma samples were lyzed in SDS sample loading buffer (as above), boiled for 10 min, and subjected to 8% SDS-PAGE. After transfer to PVDF membrane, FXIII was detected with a 1:500 dilution of goat antihuman FXIII a-chain (sc-18012, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), which detects both active and inactive FXIII. ) containing 10 U of thrombin at 37°C for 30 min followed by incubation with 5% chloroacetic acid (1 mL) at 37°C for 5 min. The highest dilution at which the clot remained insoluble was recorded. FXIII activity was determined using the following calculation: FXIII activity (%) = 100 · (maximum effective dilution factor of patient plasma/maximum effective dilution factor of control plasma).
ELISA
Platelet-released Fn in the extracellular medium was measured by an ELISA kit according to the manufacturerÕs instructions (Sun Biotech Corp., Shanghai, China). Briefly, 2 · 10 7 mL )1 gel-filtered resting or thrombin-activated platelets (1.5 IU mL )1 thrombin for 20 min) were centrifuged at 2000 · g for 10 min. A total of 100 lL supernatant samples were incubated with monoclonal anti-Fn antibody precoated wells at 37°C for 90 min. After washing, alkaline-phosphatase-conjugated antihuman Fn antibody and the substrate were successively added. The standard curve was generated at the same time, and the Fn content of the different samples was acquired from the standard curve according to the absorbance measurements.
Analysis of data
Data are presented as mean ± SD. Statistical significance was assessed by unpaired StudentÕs t-test with statistical software (SPSS version 11.0, SPSS Inc, Chicago, IL, USA).
Results
Platelet Fn content was significantly increased in hypofibrinogenemic platelets
We examined the platelet Fn content of the homozygous patient, his heterozygous parents, and healthy donors using flow cytometry, Western blot, and immunoelectron microscopy (IEM). A significant increase in the patientÕs platelet Fn content was detected by all three methods (Fig. 1A,B) , in which the mean fluorescence intensity (MFI) of the patientÕs platelet Fn by flow cytometry was 3-fold higher than that of the healthy donors (Fig. 1A) . A much higher level of Fn (immunogold particles) in platelet a-granules was also observed by IEM (data not shown). We did not detect an obvious increase in platelet Fn content in the heterozygous parents (data not shown). There was also no significant alteration of platelet TSP-1 (Fig. 1B) or vitronectin (data not shown). Because b 3 integrin is the receptor that mediates murine plasma Fn internalization [5] , we examined whether a IIb b 3 integrin (CD41) expression was upregulated on the surface of the hypofibrinogenemic patientÕs platelets. No significant difference in expression of surface a IIb b 3 integrin was found among any of the subjects (Fig. 1C: the MFI values of homozygous, heterozygous, and healthy donors were 24.3 ± 6.6, 24.5 ± 8.1, and 26.9 ± 8.4, respectively, P > 0.7) . These data are consistent with our earlier reports in fibrinogen-deficient mice [3] .
Increased Fn secretion but not cell-surface retention in thrombin-activated hypofibrinogenemic platelets
Platelet-surface Fn expression after thrombin stimulation was examined by flow cytometry and IEM. Surprisingly, while platelet Fn content was increased 3-fold in the homozygous patient, cell-surface Fn was not increased. The MFI of plateletsurface Fn was approximately 6-fold lower than that of the father and tenfold lower than that of healthy donors (Fig. 2) . Similar results were also found with electron microscopy (data not shown). Using ELISA, we observed that the patientÕs platelet Fn was primarily released into the extracellular medium after thrombin treatment ( Table 1 ). The platelet supernatant contained 2-3-fold higher levels of Fn compared with healthy donors (472.8 ± 13 ng mL )1 vs. 213.5 ± 4.7 ng mL )1
, P < 0.0005).
Decreased Fn retention is due to fibrinogen deficiency but not FXIII or platelet abnormalities
In order to exclude other possible platelet abnormalities that may cause decreased Fn retention, we examined the patientÕs platelet aggregation before and after fibrinogen transfusion (0.06 g kg
). Twenty-four hours post-transfusion, plasma fibrinogen increased to 110 mg dL )1 (approximately 40-60% of the normal level) and platelet aggregation recovered (Fig. 3A) . Interestingly, fibrinogen and Fn expression on gel-filtered platelets after thrombin stimulation was also significantly increased (Fig. 3B) . Because FXIII may play a role in the formation of covalent bonds between macromolecules (e.g. Fn and fibrin) that may contribute to Fn retention, we further assayed platelet and plasma FXIII via Western blot. No significant difference was observed (Fig. 3C) and there was no significant alteration of FXIII function in the patientÕs plasma. The highest dilution of the patientÕs plasma at which the clot remained insoluble was similar to the normal control (1:75 vs. 1:64). Thus, the decreased Fn retention on the patientÕs platelets was very probably due to fibrinogen deficiency.
Fibrin is important for Fn platelet-surface retention
Because fibrin has been reported to act as a bridging molecule for Fn retention on the platelet surface [12, 13] , we tested the hypothesis that the high retention of plateletsurface Fn in healthy donors was due to fibrin formation on the platelet surface after thrombin treatment. Gel-filtered platelets from the patient, the patientÕs parents, and healthy donors were treated with thrombin, and fibrin was detected by a fibrin-specific monoclonal antibody (Clone T2 G1), which does not recognize fibrinogen. As shown in Fig. 2 (middle panel), flow cytometry revealed high fibrin levels on the surface of platelets from healthy donors, moderate 7 gel-filtered platelets of individual subjects were separated on sodium dodecyl sulfate -polyacrylamide gel electrophoresis gel and analyzed by immunoblot with specific antibodies. Platelet vinculin and thrombospondin-1 levels were similar in all samples. The homozygous patientÕs platelets contained a significantly higher level of Fn, while the fibrinogen (Fg) level was nearly absent. In contrast, the platelet Fn and Fg contents from the parents and healthy donor were similar. (C) Surface expression of CD41 (a IIb b 3 integrin complex) analyzed by flow cytometry. There were no significant differences between the homozygous patient, the heterozygous father and the healthy control. The MFI values of homozygous, heterozygous and healthy donors were 24.3 ± 6.6, 24.5 ± 8.1 and 26.9 ± 8.4, respectively (P > 0.7).
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Fibrin Fn Healthy Healthy Fig. 2 . Decreased cell-surface fibronectin (Fn) retention in thrombinactivated hypofibrinogenemic platelets. Platelet-surface fibrinogen (Fg), fibrin and Fn expression on thrombin-stimulated platelets was measured by flow cytometry. The mean fluorescence intensity of detected Fn on the homozygous patient platelets (left curves) was approximately 6-fold lower than that of the heterozygous parent (middle curves; P < 0.05) and tenfold lower than healthy donors (right curves; P < 0.05). Fg and fibrin levels of the heterozygous parent were lower than those of the healthy control, but much higher than those of the homozygous patient (P < 0.05). Fibronectin in thrombosis and hemostasis 1743 expression on platelets from the heterozygous parents, and negligible fibrin formation on the patientÕs platelets (MFIs were 10.9 ± 2.5, 4.6 ± 0.9, and 0.84 ± 0.12, respectively, P < 0.05). Similar results were observed with IEM after immunogold staining (data not shown).
In order to further confirm the role of fibrin in Fn cellsurface retention, we directly stimulated the thrombin receptor protease activated receptor 1 with TRAP on healthy donor platelets. This peptide is able to induce platelet granule release, including release of fibrinogen and Fn, but is unable to convert fibrinogen to fibrin. As expected, TRAP stimulation resulted in cell-surface fibrinogen expression on healthy donor platelets (Fig. 4A , left panel) similar to that on thrombin-treated platelets (Fig. 2, left panel) . However, nominal fibrin was detected (Fig. 4A, middle panel) , which was coincident with very low platelet-surface levels of Fn (i.e. significant Fn was not detected on the TRAP-treated healthy platelet membranes). The MFI value of Fn expression on thrombin-treated healthy donor platelets (Fig. 2 , right panel; MFI = 10.9 ± 2.5) was significantly higher than that of TRAP-treated platelets (Fig. 4A , right panel; MFI = 0.93 ± 0.23, P < 0.05).
Using electron microscopy, we observed that thrombin stimulation resulted in significant fibrin retention on the platelet surface and was concentrated in the vicinity of platelets from the healthy donors (Fig. 4B ) and the parents (data not shown). These fibrin molecules were positively stained by gold-conjugated anti-Fn antibodies (Fig. 4B) . In contrast, TRAP treatment resulted in very poor retention of both fibrin and Fn on the platelet surface of healthy donors (Fig. 4C) . These data clearly demonstrated that thrombinconverted fibrin plays an important role in cell-surface Fn retention. 
Discussion
Fibrinogen is considered to be an essential bridging molecule required for platelet aggregation [14] [15] [16] [17] . However, we found that platelet-rich thrombi formed in both fibrinogen-deficient and fibrinogen/VWF double-deficient mice [3] and determined that fibrinogen/VWF-independent platelet aggregation can be induced in vitro under more physiological conditions (i.e. nonanticoagulated blood) [4] . Under these conditions, Fn is thought to be the most likely candidate molecule that may mediate platelet aggregation, because platelet Fn content is increased 3-5-fold in these mice. In this study, we found that the human platelet Fn content of a hypofibrinogenemic patient was also increased. Surprisingly, platelet-surface Fn expression in these hypofibrinogenemic platelets was not enhanced, but rather dramatically decreased following thrombin stimulation. We further demonstrated that fibrin formation on the platelet surface plays an important role in the surface retention of Fn. The role of Fn in thrombosis and hemostasis was recently highlighted [6] [7] [8] [9] 18, 19] . Fn is a large glycoprotein with a molecular weight of approximately 230-250 kDa. It was first discovered as a contaminant of fibrinogen preparations more than half a century ago. Subsequent studies demonstrated that it was a substrate of activated blood coagulation FXIII, a transglutaminase that covalently crosslinks Fn to fibrin. Fn usually forms as a dimer in which each polypeptide chain is linked by a pair of disulfide bonds. The amino acid sequence Arg-Gly-Asp (RGD), the consensus integrin binding motif [20] , exists in the middle portion of each polypeptide chain. This could allow Fn to possibly bridge adjacent platelets, although the distance between the two RGD sites may be too short to efficiently facilitate this process. Recent studies demonstrated that Fn self-assembly occurred on the activated platelet surface [7, 8, 18, 19] . In addition, Fn contains protein disulfide isomerase activity [21] , which may allow for non-self assembly with other thrombotic/hemostatic proteins [22] via disulfide bond exchange with proteins either on the cell surface or in the extracellular matrix. Thus, at least four possible mechanisms suggest that Fn may support thrombosis and hemostasis. These include initiating platelet adhesion via binding to Fn on the injured vessel wall, mediating platelet aggregation, contributing to the fibrin clot, and enhancing thrombus growth via Fn assembly on the platelet surface [7, 8, 18, 19, 23] .
However, there are also significant data indicating that Fn may play an inhibitory role in platelet aggregation [24] . The inhibitory effect of Fn on platelet aggregation is probably via competition with either fibrinogen or other potent integrin ligands from the plasma or ligands released from activated platelets. In addition, plasma Fn-deficient mice failed to demonstrate any overt bleeding disorder [25] . Although it has long been suspected that Fn plays a supportive role in thrombosis and hemostasis, its role in platelet aggregation remains controversial.
Our earlier studies demonstrated that platelet Fn was increased in fibrinogen-deficient mice [3] and in fibrinogen cD5 mice, which lack the C-terminal 5 amino acids of the fibrinogen c-chain, which contains the binding site for a IIb b 3 integrin [5] . After breeding fibrinogen cD5 mice with b 3 integrin-deficient mice, we observed that platelet Fn was decreased. We concluded that a IIb b 3 integrin, but not a 5 b 1 integrin (the Fn receptor), was the key receptor mediating plasma Fn internalization, and fibrinogen was a competitive ligand for this process [5] . Thus, it is not surprising that platelet Fn was also increased in our hypofibrinogenemic patient (Fig. 1A,B) . When this patient received exogenous fibrinogen transfusion, his platelet Fn content was reduced (data not shown).
It was not expected, however, that the patientÕs excess platelet Fn was unable to be retained on the platelet surface. Platelets have multiple receptors for Fn, which include a IIb b 3 , a V b 3 , and a 5 b 1 integrins. a IIb b 3 is the most abundant platelet membrane protein, with 5-12 · 10 4 copies/platelet [24] . The patient and his parents had normal levels of a IIb b 3 integrins on their platelet surfaces (Fig. 1C ), and these integrins were able to efficiently support platelet aggregation when fibrinogen was increased (Fig. 3A) or normalized [10] . It seems that the affinity between Fn and the integrin receptors is insufficient to maintain Fn surface retention at relatively low in vitro Fn concentrations (such as those used in the present study, even with supplemented divalent cations). The high ÔoffÕ ratio between Fn and integrins leads to a significant amount of Fn released into the extracellular medium after thrombin treatment (Table 1) . Our results do not exclude the possibility that, at high Fn concentrations, such as in normal plasma or a medium containing a large amount of exogenous Fn, platelet integrins may be able to retain a certain level of Fn on the platelet surface [12, 13] . However, whether these transient Fn-integrin interactions play a significant role in platelet aggregation is currently unclear. It seems that other integrin ligands such as fibrinogen (Fig. 4A ) and fibrin (Figs 2 and 4) can be retained on the cell surface and may have more potential to engage integrins on adjacent activated platelets and lead to platelet aggregation.
We found that significant fibrin formed on the surface of platelets from healthy donors and the heterozygous parents but not on the surface of platelets from the hypofibrinogenemic patient (Fig. 2) . To the best of our knowledge, this is the first report that thrombin can directly induce granule release and convert platelet-released fibrinogen to fibrin on the platelet surface. It is interesting that this newly formed fibrin (Figs 2 and 4), but not fibrinogen (Fig. 4A) , plays an important role in Fn retention on the platelet surface. We also found a significant increase in Fn retention on thrombin-activated patient platelets after fibrinogen transfusion (Fig. 3B) . It is very likely that the platelet-released transglutaminase, FXIII, may participate in fibrin-Fn complex formation on thrombin-treated platelets. This fibrin-linked Fn may play a significant role in thrombosis and hemostasis in the normal population, but may have little to no effect in afibrinogenemic/hypofibrinogenemic patients.
The most interesting and difficult question arising from the present study may be whether enhancement of platelet Fn Fibronectin in thrombosis and hemostasis 1745 content is a compensatory mechanism for hemostasis in afibrinogenemic/hypofibrinogenemic patients. As discussed above, Fn may be able to form large integrin-ligand complexes by either self-or non-self-assembly. At the site of vascular injury, large amounts of plasma Fn and thrombin are available. Triggered by platelet-vessel interactions and platelet agonists such as thrombin, platelets will release their granule proteins. The newly released Fn may dramatically enhance the local Fn concentration, which not only may extend the Fn retention time on the platelet surface but also may facilitate the Fn-Fn interaction or Fn interaction with other extracellular matrix proteins (i.e. Fn assembly). This Fn-complex formation may overcome the limitation of the short distance between the two RGD sites in the Fn dimer and could therefore play a significant role in platelet aggregation.
In summary, we found that human platelet Fn content was increased in a hypofibrinogenemic patient, which is consistent with our earlier reports in fibrinogen-deficient mice. We demonstrated that thrombin was able to convert plateletreleased fibrinogen to fibrin, which played a crucial role in Fn retention on the platelet surface. Whether the enhancement of platelet Fn internalization is a compensatory mechanism for hemostasis and how this is accomplished in afibrinogenemic/ hypofibrinogenemic patients should be of interest in future studies.
